(FM) Neurología

2021

1. A European observational study to evaluate the safety and the effectiveness of safinamide in routine clinical practice: The SynapSES trial

   Journal of Parkinson's Disease, Vol. 11, Núm. 1, pp. 187-198

2. An active lifestyle is associated with better cognitive function over time in APOE ε4 non-carriers

   Journal of Alzheimer's Disease, Vol. 79, Núm. 3, pp. 1257-1268

3. Benefit–Risk Assessment of Galcanezumab Versus Placebo for the Treatment of Episodic and Chronic Migraine Using the Metrics of Number Needed to Treat and Number Needed to Harm

   Advances in Therapy, Vol. 38, Núm. 8, pp. 4442-4460

4. Bilateral staged magnetic resonance-guided focused ultrasound thalamotomy for the treatment of essential tremor: A case series study

   Journal of Neurology, Neurosurgery and Psychiatry, Vol. 92, Núm. 9, pp. 927-931

5. Biomarker counseling, disclosure of diagnosis and follow-up in patients with mild cognitive impairment: A European Alzheimer's disease consortium survey

   International Journal of Geriatric Psychiatry, Vol. 36, Núm. 2, pp. 324-333

6. Blood pressure and risk of cognitive impairment: The role of vascular disease in neurodegeneration

   Brain Sciences, Vol. 11, Núm. 3

7. Burden and attitude to resistant and refractory migraine: a survey from the European Headache Federation with the endorsement of the European Migraine & Headache Alliance

   Journal of Headache and Pain, Vol. 22, Núm. 1

8. CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models

   Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 7

9. COVID-19 prevalence and mortality in people with epilepsy: A nation-wide multicenter study

   Epilepsy and Behavior, Vol. 125

10. Cost of fremanezumab, erenumab, galcanezumab and onabotulinumtoxinA associated adverse events, for migraine prophylaxis in Spain

    Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 21, Núm. 2, pp. 285-297

11. Degree of compliance with treatment at three months in migraine patients

    Revista de Neurologia, Vol. 72, Núm. 11, pp. 377-383

12. Delta-24-RGD, an oncolytic adenovirus, increases survival and promotes proinflammatory immune landscape remodeling in models of AT/RT and CNS-PNET

    Clinical Cancer Research, Vol. 27, Núm. 6, pp. 1807-1820

13. Development, equivalence study, and normative data of version B of the Spanish-language Free and Cued Selective Reminding Test

    Neurologia, Vol. 36, Núm. 5, pp. 353-360

14. Dissociable effects of age and Parkinson's disease on instruction-based learning

    Brain Communications, Vol. 3, Núm. 3

15. Document of revision and updating of medication overuse headache (MOH)

    Neurologia, Vol. 36, Núm. 3, pp. 229-240

16. Dúplex-Color para el diagnóstico de la estenosis carotidea

    Revista de Ecocardiografía práctica y otras Técnicas de Imagen Cardíaca (RETIC), Vol. 4, Núm. 2, pp. 55-57

17. Effects of dexmedetomidine on subthalamic local field potentials in Parkinson's disease

    British Journal of Anaesthesia, Vol. 127, Núm. 2, pp. 245-253

18. Emergency department management of epileptic seizures in patients with epilepsy

    Revista de Neurologia, Vol. 72, Núm. 12, pp. 419-425

19. Epilepsy Associated with Temporal Pole Encephaloceles: An Unrecognized Manifestation of Idiopathic Intracranial Hypertension?

    Clinical Neuroradiology, Vol. 31, Núm. 3, pp. 575-579

20. Epilepsy, sleep and neuropeptides. Future directions

    Neurology Perspectives, Vol. 1, Núm. 3, pp. 178-186